ClinicalTrials.gg
RecruitingNCT07728175Updated Oct 5, 2026

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

A Phase 1 interventional study of Sirolimus (rapamycin) and Placebo in Genetic Predisposition to Disease, Healthy Volunteer and APOE-4 Positive, sponsored by University of Missouri-Columbia. Recruiting at 1 site in United States. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Missouri-Columbia · Phase 1, Interventional, and Basic science

How we know

Updated Oct 5, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Genetic Predisposition to Disease with a site in United States — 37 open to participants now, 46 under way, none of them phase 3. Genetic Predisposition to Disease · United States.

Planned enrollment
19th of 37
225 · median 225
Started
2026
with 8 others
Phase 1
4 of 87
3 open now
Primary completion
2027-12
later than 21 of 45 live
Registered
84th of 87
by date

Among the 87 studies in Genetic Predisposition to Disease with a site in United States, this one is the 19th largest by planned enrollment of the 37 interventional ones that give a count, is one of 9 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 21 of the 45 other live ones, and was the 84th registered.

Genetic Predisposition to Disease

242 studies on the registry are indexed under Genetic Predisposition to Disease; 96 are open to participants now.

Browse Genetic Predisposition to Disease studies →

Open to participants now

37 of the 87 studies in Genetic Predisposition to Disease with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Genetic Predisposition to Disease studies recruiting now, 36 (51%) set no upper age limit and 28 (39%) stop at 75 or younger; 25 take children under 18; 23 take healthy volunteers.

This study: 45 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Genetic Predisposition to Disease with a site in United States, or all of them as a file.
02

Study summary

Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.

Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.

There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.

Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams

03

Conditions studied

  • Genetic Predisposition to Disease
  • Healthy Volunteer
  • APOE-4 Positive

Keywords

  • ApoE4 positive
  • Cerebral Blood Flow
  • Sirolimus
  • Rapamycin
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide
  2. Sex assigned at birth: female
  3. 45-65 years old
  4. Able to perform self-care and activities of daily living with no or minimal assistance
  5. status or use of highly effective . Post-menopausal is defined as either

    • 12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age-appropriate, history of vasomotor symptoms)
    • surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to screening. For oophorectomy alone, post-menopausal status must be confirmed by follow-up hormone level assessment
    • Highly effective contraception includes intrauterine devices (IUD), oral contraceptives, or other hormonal contraceptives including injectables, transdermal patches, implants or vaginal rings, or refraining from heterosexual intercourse during the 4 weeks of taking the study drug and for 2 weeks after no longer taking the study drug
  6. Body weight of ≥ 40 kg
  7. Ability to effectively communicate with the investigator and comply with study requirements

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of mild cognitive impairment (MCI), dementia, or Alzheimer's disease
  2. ≥ 35 (based on MRI feasibility)
  3. Type 1 diabetes or poorly controlled type 2 diabetes ( ≥ 6.5%)
  4. History of skin ulcers or poor wound healing
  5. Current tobacco or illicit drug use or alcohol abuse (defined as ≥ 3 per day or ≥ 7 per week for women) (Per NIAAA guidelines)
  6. Use of anti- or anti-coagulant medications other than aspirin
  7. Required use of medications that affect cytochrome P450 3A4 () or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)
  8. therapy within the last year
  9. Chemotherapy or radiation treatment within the last year
  10. Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities
  11. Untreated hypertriglyceridemia (fasting triglycerides \< 300 mg/dl)
  12. Current or chronic significant history of pulmonary disease
  13. Chronic heart failure
  14. Pregnancy or lactation
  15. Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or
  16. Poorly controlled blood pressure (systolic BP > 160 or diastolic BP > 100 mmHg)
  17. Active inflammatory, COVID-19, , infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness
  18. History of, or MRI, or CT positive for, any space occupying brain lesion, including mass effect or abnormal intracranial pressure
  19. Organ transplant recipients
  20. History of Stroke
  21. History of ruptured intracranial aneurysm
  22. History of within the past 2 years, with the following exceptions:

    • Localized basal cell or squamous cell carcinoma of the skin
    • Prostate cancer confined to the gland (AJCC stage T2N0M0 or better)
    • Cervical carcinoma in situ
    • Breast cancer localized to the breast
  23. History of epilepsy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
225 participants (estimated)

Study arms

  • Active comparator
    Sirolimus

    Drug: Sirolimus (rapamycin)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants in Sirolimus arm will receive Sirolimus.

  • DrugPlacebo

    Participants in the Placebo arm will receive Placebo

06

What researchers measure

Primary outcomes

  1. Change in Cerebral Blood Flow as measured by MRI

    Rate of blood perfusion expressed as mL/100g/min globally and regionally

    Time frame: Baseline to 4 weeks

Secondary outcomes

  1. Measure the change in plasma Marker-cytokine using a Meso Scale Discovery (MSD) analyzer.

    Time frame: Baseline to 4 weeks

  2. Measure baseline to post-treatment changes in Plasma Markers-AD pathology using a Meso Scale Discovery (MSD) analyzer

    Time frame: Baseline to 4 weeks

  3. Measure brain function connectivity by fMRI

    Time frame: Baseline to 4 weeks

  4. Measurement of blood brain barrier by MRI

    Time frame: Baseline to 4 weeks

  5. Measurement of brain oxygenation by MRI

    Time frame: Baseline to 4 weeks

  6. Measurement of glucose uptake in the brain by PET imaging

    Glucose uptake in the brain globally and regionally

    Time frame: Baseline to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007 Aug 1;76(3):391-6. PubMed 17708140 ↗
  • Lin AL, Aware C, Neher C, Hamdi M, Ericsson A, Khegai O, Patrie J, Kurt M, Govindarajan M, Woods C, Ivanich K, Beversdorf D, Cheng J, Balchandani P, Gonzales M, Altes T. Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers. Res Sq [Preprint]. 2025 Mar 19:rs.3.rs-6214340. doi: 10.21203/rs.3.rs-6214340/v1. PubMed 40166019 ↗
  • Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M, Kappos L, Goedert M, Tolnay M, Winkler DT. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS One. 2013 May 7;8(5):e62459. doi: 10.1371/journal.pone.0062459. Print 2013. PubMed 23667480 ↗
  • Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014 Dec 24;6(268):268ra179. doi: 10.1126/scitranslmed.3009892. PubMed 25540326 ↗
  • Lelegren M, Liu Y, Ross C, Tardif S, Salmon AB. Pharmaceutical inhibition of mTOR in the common marmoset: effect of rapamycin on regulators of proteostasis in a non-human primate. Pathobiol Aging Age Relat Dis. 2016 Jun 23;6:31793. doi: 10.3402/pba.v6.31793. eCollection 2016. PubMed 27341957 ↗
  • Sills AM, Artavia JM, DeRosa BD, Ross CN, Salmon AB. Long-term treatment with the mTOR inhibitor rapamycin has minor effect on clinical laboratory markers in middle-aged marmosets. Am J Primatol. 2019 Feb;81(2):e22927. doi: 10.1002/ajp.22927. Epub 2018 Oct 12. PubMed 30311681 ↗
  • Tardif S, Ross C, Bergman P, Fernandez E, Javors M, Salmon A, Spross J, Strong R, Richardson A. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J Gerontol A Biol Sci Med Sci. 2015 May;70(5):577-87. doi: 10.1093/gerona/glu101. Epub 2014 Jul 19. PubMed 25038772 ↗
  • Ross C, Salmon A, Strong R, Fernandez E, Javors M, Richardson A, Tardif S. Metabolic consequences of long-term rapamycin exposure on common marmoset monkeys (Callithrix jacchus). Aging (Albany NY). 2015 Nov;7(11):964-73. doi: 10.18632/aging.100843. PubMed 26568298 ↗
  • Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010 Apr 1;5(4):e9979. doi: 10.1371/journal.pone.0009979. PubMed 20376313 ↗
  • Lin AL, Parikh I, Yanckello LM, White RS, Hartz AMS, Taylor CE, McCulloch SD, Thalman SW, Xia M, McCarty K, Ubele M, Head E, Hyder F, Sanganahalli BG. APOE genotype-dependent pharmacogenetic responses to rapamycin for preventing Alzheimer's disease. Neurobiol Dis. 2020 Jun;139:104834. doi: 10.1016/j.nbd.2020.104834. Epub 2020 Mar 12. PubMed 32173556 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2026
First posted
Jul 27, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 7, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
University of Missouri is now Recruiting
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    University of Missouri is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07728175
Responsible party
Ai-Ling Lin, PhD (Professor of Radiology, University of Missouri-Columbia) — Principal investigator
First posted
Jul 27, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 7, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Nathan Bresette
Contact
nbhtd@missouri.edu
Ai-Ling Lin, PhD
principal investigator · University of Missouri-Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion